| ￥2100 | |
| Z04303-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 23.6 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of CD200/OX-2, His, Mouse is greater than 95% as determined by SEC-HPLC. »
CD200/OX-2, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Mouse CD200 R1, His Tag immobilized on CM5 Chip can bind CD200/OX-2, His, Mouse, His Tag with an affinity constant of 1.19 μM as determined in SPR assay (Biacore T200). »
| Target Background | CD200 and its receptors are highly expressed in the lung, on epithelial cells and leukocytes, and emerging evidence links dysregulation of the CD200 pathway with asthma. Moreover, pharmacological modulation of CD200 receptors was shown to improve clinical and inflammatory outcomes of preclinical asthma models. |
| Synonyms | CD200; MOX1; MOX2; My033; MRC; OX-2; OX2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
